A Quick News Quiz on GU Cancers

Article

What class of agents negatively affects responses in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors? Which gender is significantly more likely to undergo radical cystectomy for bladder cancer? Test your knowledge on genitourinary cancers in our latest quiz.

What class of agents negatively affects responses in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors? Which gender is significantly more likely to undergo radical cystectomy for bladder cancer? Test your knowledge on genitourinary cancers in our latest quiz.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is: A. Bicalutamide. According to the study, patients received oral bicalutamide 150 mg day during and after radiation therapy. At 12 years, overall survival was 76.3% in the bicalutamide group vs 71.3% in the placebo group (P = .04). Incidence of death from prostate cancer was 13.4% vs 5.8% (P < .001), and cumulative incidence of metastatic prostate cancer was 23% vs 14.5% (P =.005), respectively.

 

Question 2:

Answer and Question 3 on Next Page »

The correct answer is: A. Cabozantinib. Median overall survival was 21.4 months with cabozantinib vs 16.5 months with everolimus, according to the study. The authors concluded, “cabozantinib is an important new treatment option for this patient population.”

 

Question 3:

Answer and Question 4 on Next Page »

The correct answer is: D. 240 mg intravenously every 2 weeks.

 

Question 4:

Answer and Question 5 on Next Page »

The correct answer is: A. Antibiotics. The study found that patients had received mostly beta-lactamases and fluoroquinolones. Objective response rates were lower and there was a negative trend for overall survival.

Question 5:

Answer on Next Page »

The correct answer is: B. False. Women in the study were older, more likely to be non-Caucasian, had increased comorbidities, and presented with more advanced disease (all P < .001). Women had significantly worse cancer-specific survival than men. Although “delay from diagnosis to radical cystectomy was associated with worse survival,” the authors noted, “delay to surgery did not account for this deceased survival among women.” They concluded, “these findings support further research discerning bladder carcinogenesis according to gender.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content